Hot Longevity Mandate: Asia-Based Pharma

The pharmaceutical company is based in Korea. The company’s current marketing portfolio are mostly made of branded products licensed in from overseas partners. For the R&D activity, the company has several clinical pipelines under global phase II in the area of CNS and diabetes, CNS clinical pipeline under phase III in Korea, and a late preclinical stage oncology product as well as an early preclinical candidates targeting TEC kinase family developed in-house. The company is actively searching for innovative candidates and products around the world to incorporate into its pipeline and product portfolio. The firm has ample experience across various types of partnerships with overseas companies and is flexible in terms of the business structure. The firm is interested globally, including world-wide major territories.

The company is currently seeking promising novel therapeutic candidates to incorporate into its pipeline. In terms of indications, the firm is indication agnostic with added interest in movement disorders, CNS, liver disease and immunology. The company is also interested in oncology indications (small molecule or biologics with novel MoA). The firm prefers assets both in early/late non-clinical development stage as well as in early clinical development stage. The firm is also interested in obtaining distribution rights for innovative treatment in Phase III or in marketing authorization process.

The company is open to working with companies anywhere in the world, and has no set requirements for partners; The company is able to work with virtual drug companies by leveraging the firm’s own capabilities and third party relationships.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

Hot AI Mandate: VC Looks for Tech-based Digital Health & Diagnostics Companies With China Angles

A venture capital firm founded in 2002 is looking to invest in tech-based digital health and diagnostics companies looking to expand to the Chinese market. Ascend primarily invests in European companies, but will consider companies based in the US as well. The firm looks to leverage their connections to China and the Chinese market on behalf of its portfolio companies. The firm looks to invest between $2-10M in companies, taking a 15-30% equity stake. The firm prefers to be a lead investor, taking an active role in their portfolio companies, and will invest in about 2 companies a year, depending on their fund cycle. In cases where Ascend does not invest funds, they are also willing to offer consulting services for equity, connecting companies with strategic partners in China.

The firm has an additional partnership model that, instead of direct investment, licenses technologies through a Chinese platform company, acting as a focused distributor for entry into the Chinese market. This is Ascend’s alternate investment approach to bringing these technologies to the Chinese market, by utilizing this Chinese platform company to serve as their portfolio company’s representative in China to navigate the regulatory environment and spearhead all of the sales and marketing.

The firm is interested in tech companies that are not consumer focused. The firm looks for companies such as diagnostics tools or AI/machine learning technologies in the healthcare space. The firm has some experience with pathology diagnostic related companies, but is willing to consider other areas as well. The firm prefers to invest in a few companies within the same area, choosing complementary technologies between their portfolio companies. Ascend will consider companies with technologies that are in development or in pilot stages.

The firm is an active investor and takes a board seat for every company in which they invest.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

Hot AI Mandate: US-based VC Interested in Technologies Related to Precision Medicine

A medical technology venture firm was founded in 2013 and based in Concord, MA. The firm makes equity investments in early stage companies developing diagnostic technologies to accelerate the trend of precision medicine. The firm seeks a leading investment position and deep involvement with its portfolio companies. Typical investment ranges from $5-15 M and is calibrated to milestone attainment. With a global view and global operational capabilities, the firm is currently seeking opportunities around the world.

The firm focuses on three market segments that support knowledge-generating precision medicine diagnosis: 1) mobile health, data analytics, and healthcare IT; 2) high specificity in-vivo and in-vitro diagnostics; and 3) diagnostic technologies that guide or are a companion to precision therapies. The firm is looking for technologies that will dramatically improve patient health and have the potential for global markets and scale.

The firm is looking for experienced management teams with deep domain expertise. The firm typically requests board representation post-investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

Hot AI Mandate: China-based VC Interested In Global Life Science/Healthcare Opportunities

A venture capital firm was founded in 2016 and has its main office in Shanghai, China. The firm currently manages three funds including RMB Fund I and Fund II, with a venture USD fund. On average, the initial size of investment is in the $1-6M range, but the firm has the capacity to invest more in companies they identify as a strong fit. The firm has 5 innovation centers across China focusing on different special areas in Life Sciences and medical devices. With over 8 years of operating experience of international medical technology incubators, the firm looks to tailor its services to help portfolio companies reaching key value-added milestones. The firm will consider opportunities based in China and around the globe. The firm actively supports global companies to fast land China market by leveraging the fund’s connections

The firm is a flexible and opportunistic investor that is currently considering Therapeutics, Medical Devices, Diagnostics, AI, and Biotechnology R&D Services. The firm is opportunistic in terms of sub-sector and indication and is willing to consider companies targeting orphan indications. The firm is open to novel medical devices of all FDA regulatory pathways, including 510k and PMA. In terms of therapeutics, The firm will look at products in pre-clinical stages. Regarding medical devices and diagnostics, the firm will invest at any stage of development.

The firm will invest in privately held companies only, and the firm can participate as either lead or co-investor. The firm has no specific requirements for the management team. The firm may take a board seat in applicable cases.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

Global Roadshow Prep Course

By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the LSN Partnering Conference Series

The roadshow is coming this September! The Global Roadshow Prep Course is a hands-on, comprehensive, one-day course designed to set up the early-stage life science executive for success as they conduct their global fundraise. The course is available to 24 early-stage CEOs and includes complimentary registration to RESI Partnering Week with Premier Partnering access for only $1,950! If you’re starting an early-stage raise, this one-day course should be the first stop on your global roadshow!

Global Roadshow Prep Course
Friday, September 3
9:00 AM – 5:00 PM EDT
Friday, September 10
9:00 AM – 5:00 PM EDT

Life Science Nation (LSN)’s Global Roadshow Preparation course is a one-day fundraising and licensing campaign preparation class designed to set up the early-stage executive seeking institutional funding and licensing for success and strategic partnerships. This course is hands-on, providing one-on-one mentorship as we explore the process, materials, research, and practices that are essential for an early-stage fundraise and licensing opportunities.

Learning objectives include, but are not limited to:

  • Branding and messaging communicating your company’s unique story and market value
  • Understanding and creating collateral for use in a pitch setting, including tagline, elevator pitch, executive summary, and slide deck
  • Discovering the values of different types of investors and identifying the best fit -based leads
  • Communicating effectively in order to secure a meeting and following up to develop an ongoing relationship
  • Engaging in successful partnering strategies to obtain funding and strategic partnership

“The greatest lesson is that my background and experiences weren’t enough to enable me to do this without help. I am a career scientist and R&D operations manager with an MBA in pharmaceutical management. I had all of the knowledge and tools at my disposal to do what LSN did. But I couldn’t put it all together. I needed LSN to come in and do what they do best.”

  • Richard Austin, PhD, MBA, President & CEO, Reglagene

Global Tech Hub Gathering at RESI Partnering Week September

By Gregory Mannix, Vice President International Business Development, General Manager Europe, LSN

Innovation is booming. Whether it originates in a university lab, a hospital or a research institute, technology hubs like incubators and accelerators are helping these early-stage spinouts become companies that can move their technologies to the next phase. They play a key role globally.

At RESI Partnering Week, September 13-17, we will once again pay tribute to and showcase Tech Hubs from around the world. These important organizations will have the chance to be featured on the event Live Agendas and showcase their programs and companies on a dedicated landing page. Plus, their constituent companies will be able to register for Digital RESI September, RESI AI, or RESI Longevity at a discounted price and pitch in an Innovator’s Pitch Challenge, getting valuable experience fielding live questions from a panel of investors.

RESI and Tech Hubs: partners in a common mission.

Past Tech Hub Participants
 

For more information, contact resi@lifesciencenation.com

Making the IPC Work for You

By Rory McCann, Marketing Manager & Conference Producer, LSN

The Innovator’s Pitch Challenge (IPC) is an opportunity for early-stage companies to pitch to a live panel of active investors in their sector, but the pitch session is only a small part of the challenge. A large amount of thought, creativity, and effort goes into the data and presentation of a company’s pitch materials that will be hosted on a dedicated webpage, and the time put into their longer recorded pitch goes beyond the average 4-minute video. The IPC is meant to be one stop along the way to preparing companies for building strategic partnerships with well-matched investors. I chatted with the Life Science Nation research team to learn more about how companies can truly take advantage of this unique opportunity and make it work for them long-term.

What is the greatest value of pitch sessions like the Innovator’s Pitch Challenge?

The pitch session is a unique opportunity for companies to get a great deal of exposure to a large investor audience. With their marketing collateral available on a dedicated page along with a pitch video, all conference attendees can find out more about the company and what makes it unique. Furthermore, the live Q&A session allows the companies to interact with investor judges who are in their sector, along with a live audience to watch their pitch, which often includes other investors interested in learning more about their technology. While there is a great opportunity to find investors who are a fit, more than anything, the IPC is a way to hone your pitch, to make sure you are fully prepared for any questions you may get asked when you are in an initial investor meeting.

What makes a strong pitch page and video?

A strong pitch page and video are centered around good marketing collateral and a company’s ability to tell their story in a concise and cogent manner. A good pitch video should cover these points:

  1. What the company does/what is the technology
  2. What makes the company unique
  3. What is the target market and its size
  4. What milestones you have achieved, and what milestones you are looking to meet with this fundraise

What should companies do to prepare for their live pitch?

Companies only have one minute to refresh the memories of the investor panel before the Q&A starts, so they should make sure to highlight the key value proposition of their company in that minute. It takes practice to give a clear description of their company in so short a time – they should practice! Also, they should think about all the questions an investor may ask, and they should remember, they won’t necessarily all be about the technology. Investors are also interested in a company’s exit strategy, go-to-market strategy, any regulatory hurdles that may exist, etc. An investor needs to know a lot more than just the science, and their decisions won’t be based solely on that either.

What makes a company stand out in a live pitch?

A company stands out by making a clear elevator pitch, followed by clear and cogent responses to investor questions. A company needs to make sure to really listen to the question, and to address it fully. Also, a company should try to avoid bluffing their way through a question they may not have the answer to – investors can tell. It’s OK not to always have all the answers, if the company needs to look into something further, and it’s better to acknowledge that. More than anything, these live sessions are a great way for entrepreneurs to show the passion they have for their companies.

What advice would you offer a company to make the most of their pitch session post-conference?

After each live Q&A session, the RESI team connects all of the companies and investors who participated in their assigned session via group e-mail. The company should make sure to follow up with the investors who were on the panel, to get any tips and feedback they can provide. This may lead to fruitful conversations, a referral to another investor they know who may be interested, or even just some great feedback. This is an excellent opportunity to find out what works and what doesn’t, and to see what questions the company is asked frequently, to know what information they may want to prepare ahead of time or add to their existing collateral. Cultivating and maintaining these relationships will help companies grow their industry network, enabling them to connect with more investors and industry experts in the future.

Are you interested in joining the IPC? Join us for RESI Partnering Week, September 13-17, and join a session that’s a fit for you!

Apply for RESI
Sept.13-15
Apply for RESI AI
Sept.16-17
Apply for RESI Longevity
Sept.16-17